ReviewNeuroscience and biobehavioral reviews2017
Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons.
Review in Neuroscience and biobehavioral reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- Nociceptive responses and resting-state functional connectivity of the human midbrain tegmentum.Brain structure & function · 2026Article
- Can the incentive-sensitization theory of addiction incorporate addiction to opioid drugs?Psychopharmacology · 2026Review
- Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.Journal of clinical medicine · 2026Review
- Review
- Inhibition of ventral tegmental area projections to the paraventricular thalamus attenuates conditioned cues-induced heroin seeking behavior in rats.Metabolic brain disease · 2025Article
- Investigating the effect of Arvcf reveals an essential role on regulating the mesolimbic dopamine signaling-mediated nicotine reward.Communications biology · 2025Article
- Peripherally Restricted Fused Heterocyclic Peptidomimetic Multifunctional Opioid Agonists as Novel, Potent Analgesics.ACS medicinal chemistry letters · 2025Article
- Buprenorphine's Effect on the Human Immune System and Inflammation.Clinical and translational science · 2025Review
- Molecular and cellular basis of mu-opioid receptor signaling: mechanisms underlying tolerance and dependence development.Frontiers in neuroscience · 2025Review
- Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance.Neuropharmacology · 2024Article
- A master regulator of opioid reward in the ventral prefrontal cortex.Science (New York, N.Y.) · 2024Article
- Blockade of the Dopamine DNeuroscience bulletin · 2023Article
- The rostromedial tegmental nucleus RMTg is not a critical site for ethanol-induced motor activation in rats.Psychopharmacology · 2023Article
- Opioid-induced short-term consciousness improvement in patients with disorders of consciousness.Frontiers in neuroscience · 2023Article
- The Mesoscopic Connectome of the Cholinergic Pontomesencephalic Tegmentum.Frontiers in neuroanatomy · 2022Article
- A novel cholinergic projection from the lateral parabrachial nucleus and its role in methamphetamine-primed conditioned place preference.Brain communications · 2022Article
- A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide YNeuroscience and biobehavioral reviews · 2021Review
- The rostromedial tegmental (RMTg) "brake" on dopamine and behavior: A decade of progress but also much unfinished work.Neuropharmacology · 2021Review
- Naloxone precipitated withdrawal increases dopamine release in the dorsal striatum of opioid dependent men.Translational psychiatry · 2021Article
- Activation of trace amine-associated receptor 1 selectively attenuates the reinforcing effects of morphine.British journal of pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
Opioids, such as morphine or heroin, increase forebrain dopamine (DA) release and locomotion, and support the acquisition of conditioned place preference (CPP) or self-administration. The most sensitive sites for these opioid effects in rodents are in the ventral tegmental area (VTA) and rostromedial tegmental nucleus (RMTg). Opioid inhibition of GABA neurons in these sites is hypothesized to lead to arousing and rewarding effects through disinhibition of VTA DA neurons. We review findings that the laterodorsal tegmental (LDTg) and pedunculopontine tegmental (PPTg) nuclei, which each contain cholinergic, GABAergic, and glutamatergic cells, are important for these effects. LDTg and/or PPTg cholinergic inputs to VTA mediate opioid-induced locomotion and DA activation via VTA M5 muscarinic receptors. LDTg and/or PPTg cholinergic inputs to RMTg also modulate opioid-induced locomotion. Lesions or inhibition of LDTg or PPTg neurons reduce morphine-induced increases in forebrain DA release, acquisition of morphine CPP or self-administration. We propose a circuit model that links VTA and RMTg GABA with LDTg and PPTg neurons critical for DA-dependent opioid effects in drug-naïve rodents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.